New combo for lung cancer

Roche is testing a new combination of anti-TIGIT antibody Tiragolumab and Tecentriq PD-L1 checkpoint inhibitor. This combination has been shown to be effective in a lung cancer trial. The combination supports the logical assumption that two immunotherapy drugs are better than one.

At the ESMO Cancer Congress, Roche has presented the updated results of phase 2 CITYSCAPE trial. This study compared Tecentriq and Tiragolumab combination with Tecentriq alone as a first-line treatment for non-small cell lung cancer. After several years of study, the combo regimen reduced the risk of worsening illness or death by 38% compared to Tecentriq mono regimen. New evidence suggests that the dual pathway works much better in tumors with high PD-L1 protein expression.

Source: PharmaPhorum